» Articles » PMID: 22701724

Deregulated MiRNAs in Hereditary Breast Cancer Revealed a Role for MiR-30c in Regulating KRAS Oncogene

Overview
Journal PLoS One
Date 2012 Jun 16
PMID 22701724
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Aberrant miRNA expression has been previously established in breast cancer and has clinical relevance. However, no studies so far have defined miRNAs deregulated in hereditary breast tumors. In this study we investigated the role of miRNAs in hereditary breast tumors comparing with normal breast tissue. Global miRNA expression profiling using Exiqon microarrays was performed on 22 hereditary breast tumors and 15 non-tumoral breast tissues. We identified 19 miRNAs differentially expressed, most of them down-regulated in tumors. An important proportion of deregulated miRNAs in hereditary tumors were previously identified commonly deregulated in sporadic breast tumors. Under-expression of these miRNAs was validated by qRT-PCR in additional 18 sporadic breast tumors and their normal breast tissue counterparts. Pathway enrichment analysis revealed that deregulated miRNAs collectively targeted a number of genes belonging to signaling pathways such as MAPK, ErbB, mTOR, and those regulating cell motility or adhesion. In silico prediction detected KRAS oncogene as target of several deregulated miRNAs. In particular, we experimentally validated KRAS as a miR-30c target. Luciferase assays confirmed that miR-30c binds the 3'UTR of KRAS transcripts and expression of pre-miR-30c down-regulated KRAS mRNA and protein. Furthermore, miR-30c overexpression inhibited proliferation of breast cancer cells. Our results identify miRNAs associated to hereditary breast cancer, as well as miRNAs commonly miss-expressed in hereditary and sporadic tumors, suggesting common underlying mechanisms of tumor progression. In addition, we provide evidence that KRAS is a target of miR-30c, and that this miRNA suppresses breast cancer cell growth potentially through inhibition of KRAS signaling.

Citing Articles

MicroRNAs as promising biomarkers and potential therapeutic agents in breast cancer management: a comprehensive review.

Mohan Lal P, Hamza Siddiqui M, Soulat A, Mohan A, Tanush D, Tirath K Ann Med Surg (Lond). 2024; 86(6):3543-3550.

PMID: 38846828 PMC: 11152842. DOI: 10.1097/MS9.0000000000002075.


Unraveling Roles of miR-27b-3p as a Potential Biomarker for Breast Cancer in Malay Women via Bioinformatics Analysis.

Jusoh A, Al-Astani Bin Tengku Din T, Abdullah-Zawawi M, Wan Abdul Rahman W, Nafi S, Romli R Int J Mol Cell Med. 2024; 12(3):257-274.

PMID: 38751652 PMC: 11092903. DOI: 10.22088/IJMCM.BUMS.12.3.257.


Estrogen receptor alpha mutations regulate gene expression and cell growth in breast cancer through microRNAs.

Arnesen S, Polaski J, Blanchard Z, Osborne K, Welm A, OConnell R NAR Cancer. 2023; 5(2):zcad027.

PMID: 37275275 PMC: 10233889. DOI: 10.1093/narcan/zcad027.


Dexmedetomidine alleviates airway hyperresponsiveness and allergic airway inflammation through the TLR4/NF‑κB signaling pathway in mice.

Xiao S, Wang Q, Gao H, Zhao X, Zhi J, Yang D Mol Med Rep. 2022; 25(3).

PMID: 35014685 PMC: 8778652. DOI: 10.3892/mmr.2022.12590.


Effects and prognostic values of miR-30c-5p target genes in gastric cancer via a comprehensive analysis using bioinformatics.

Hu S, Liu H, Zhang J, Li S, Zhou H, Gao Y Sci Rep. 2021; 11(1):20584.

PMID: 34663825 PMC: 8523699. DOI: 10.1038/s41598-021-00043-w.


References
1.
Spandidos D . Oncogene activation in malignant transformation: a study of H-ras in human breast cancer. Anticancer Res. 1987; 7(5B):991-6. View

2.
Ventura A, Jacks T . MicroRNAs and cancer: short RNAs go a long way. Cell. 2009; 136(4):586-91. PMC: 3910108. DOI: 10.1016/j.cell.2009.02.005. View

3.
Dunn K, Espino P, Drobic B, He S, Davie J . The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochem Cell Biol. 2005; 83(1):1-14. DOI: 10.1139/o04-121. View

4.
McCubrey J, Steelman L, Chappell W, Abrams S, Wong E, Chang F . Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2006; 1773(8):1263-84. PMC: 2696318. DOI: 10.1016/j.bbamcr.2006.10.001. View

5.
Morrissey E, Diaz-Uriarte R . Pomelo II: finding differentially expressed genes. Nucleic Acids Res. 2009; 37(Web Server issue):W581-6. PMC: 2703955. DOI: 10.1093/nar/gkp366. View